Physician profile
Trejon A Brignac
NPI 1891285516
$2,176.54
in general payments reported to CMS, 2019-2025
21 companies · $672 in 2025
The $672 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $201 · 2023: $355 · 2024: $498 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $639.81 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $283.47 | 2021-2023 | |
| Lilly USA, LLC | $168.71 | 2021-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $150.97 | 2021-2024 | Austedo Xr |
| Alkermes, INC. | $126.89 | 2023-2025 | Lybalvi, Aristada |
| Collegium Pharmaceutical, INC. | $122.10 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.02 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.58 | 2021-2024 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $80.80 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $58.50 | 2021-2022 | |
| Ardelyx, INC. | $45.05 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $43.45 | 2021 | |
| Gilead Sciences, INC. | $39.89 | 2025 | Epclusa |
| Ironwood Pharmaceuticals, INC | $37.11 | 2023-2024 | Linzess |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.03 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $32.39 | 2021 | |
| Sanofi Pasteur INC. | $17.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.16 | 2021 | |
| Astellas Pharma US INC | $13.21 | 2024 | Veozah |
| Lundbeck LLC | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trejon Brignac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.